Kamada (KMDA) EPS (Weighted Average and Diluted) (2012 - 2026)
Kamada (KMDA) reported EPS (Weighted Average and Diluted) of $59028.6 for Q1 2026, down 55.39% on a YoY basis from $132314.3 in Q1 2025, and up 249.81% quarter-over-quarter from $16874.3 in Q4 2025.
Kamada (KMDA) EPS (Weighted Average and Diluted) (2012 - 2026) Analysis & Trends
Kamada has reported EPS (Weighted Average and Diluted) for 15 years, with the latest figure at $59028.6 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 55.39% year-over-year to $59028.6; the trailing twelve-month figure through Mar 2026 stood at $59028.6 (down 55.39% YoY), and the FY2025 full-year result was $76388.6, up 56.46% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $59028.6, up from $16874.3 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $132314.3 in Q1 2025, with the low at -$45700.0 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged $25938.4 across 5 years, with a median of $22394.4 in 2024.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) tumbled 357.52% — and 2024, when it surged 139016.53%.
- Kamada's EPS (Weighted Average and Diluted) stood at $42057.1 in 2022, then retreated by 19.82% to $33720.0 in 2023, then plunged by 54.83% to $15232.0 in 2024, then advanced by 10.78% to $16874.3 in 2025, then soared by 249.81% to $59028.6 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $59028.6 (Q1 2026), $16874.3 (Q4 2025), and $29120.7 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -0.40 |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.80 |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -0.40 |
| 10 | Kamada | 505.05 | -73.15 Mn | 19.12 Mn | 59,028.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59,028.57 |
| Dec 31, 2025 | 16,874.29 |
| Sep 30, 2025 | 29,120.69 |
| Jun 30, 2025 | 21.74 |
| Mar 31, 2025 | 132,314.29 |
| Dec 31, 2024 | 15,232.00 |
| Sep 30, 2024 | 22,394.44 |
| Jun 30, 2024 | -487.59 |
| Mar 31, 2024 | 62,825.00 |
| Dec 31, 2023 | 33,720.00 |
| Sep 30, 2023 | 53,716.67 |
| Jun 30, 2023 | 45,925.00 |
| Mar 31, 2023 | -45.23 |
| Dec 31, 2022 | 42,057.14 |
| Sep 30, 2022 | 4,116.58 |
| Jun 30, 2022 | -30,161.54 |
| Mar 31, 2022 | -45,700.00 |
| Dec 31, 2021 | -42,400.00 |
| Sep 30, 2021 | -14,083.33 |
| Jun 30, 2021 | 11,712.50 |